Digital Health Awards Will Honor Tech That Dramatically Improves Healthcare
UCSF and Health Hub have announced the launch of the first annual UCSF Digital Health Awards.
University of California San Francisco
A two-week course of an experimental immunotherapy called teplizumab dramatically reduced type 1 diabetes (T1D) diagnosis rates in people at high risk for the disease, according to newly published phase II clinical trial results. This is the first time a drug has been able to delay or prevent the disease, which affects 2 million people in the United States.